- Home
- MGTX vs CSTL Comparison
MGTX vs CSTL Comparison
Compare MGTX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGTX
- CSTL
- Stock Information
- Founded
- MGTX 2015
- CSTL 2007
- Country
- MGTX United States
- CSTL United States
- Employees
- MGTX N/A
- CSTL N/A
- Industry
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- CSTL Medical Specialities
- Sector
- MGTX Health Care
- CSTL Health Care
- Exchange
- MGTX Nasdaq
- CSTL Nasdaq
- Market Cap
- MGTX 670.2M
- CSTL 697.9M
- IPO Year
- MGTX N/A
- CSTL 2019
- Fundamental
- Price
- MGTX $7.51
- CSTL $21.64
- Analyst Decision
- MGTX Strong Buy
- CSTL Strong Buy
- Analyst Count
- MGTX 2
- CSTL 6
- Target Price
- MGTX $24.00
- CSTL $37.67
- AVG Volume (30 Days)
- MGTX 325.1K
- CSTL 461.9K
- Earning Date
- MGTX 08-14-2025
- CSTL 11-03-2025
- Dividend Yield
- MGTX N/A
- CSTL N/A
- EPS Growth
- MGTX N/A
- CSTL N/A
- EPS
- MGTX N/A
- CSTL N/A
- Revenue
- MGTX $37,917,000.00
- CSTL $346,269,000.00
- Revenue This Year
- MGTX $145.67
- CSTL N/A
- Revenue Next Year
- MGTX $167.61
- CSTL N/A
- P/E Ratio
- MGTX N/A
- CSTL N/A
- Revenue Growth
- MGTX 366.84
- CSTL 20.40
- 52 Week Low
- MGTX $3.86
- CSTL $14.59
- 52 Week High
- MGTX $8.98
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- MGTX 46.65
- CSTL 49.89
- Support Level
- MGTX $7.39
- CSTL $22.54
- Resistance Level
- MGTX $7.91
- CSTL $24.74
- Average True Range (ATR)
- MGTX 0.36
- CSTL 1.12
- MACD
- MGTX 0.01
- CSTL -0.18
- Stochastic Oscillator
- MGTX 39.78
- CSTL 28.02
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.